Following completion of the dose escalation phase in relapsed/refractory acute leukemia patients with FLT3 mutations, Biomea ...

Q1 2025 Earnings Call Transcript May 15, 2025 Operator: Thank you for standing by. And welcome to Invivyd’s First Quarter ...

ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in ...

First Cohort Completed in PRECISE-AD Trial Evaluating PMN310 in Alzheimer's Disease Six Month Interim Results Expected in 1H 2026 Topline Results Anticipated by end of 2026 CAMBRIDGE, Massachusetts ...

We did some things like this in our PK/PD project with Sebastian1 ... 1 sd is actually pretty damn big, given that "1 sd" represents all the variation across kids. In a setting where true effects are ...

Pharmacokinetic (PK) model generated based on the single ascending dose (SAD) data and the first multiple ascending dose (MAD) cohort. Model confirms the predicted dosing regimen for phase 2 ...

Pharmacokinetic (PK) model generated based on the single ascending dose (SAD) data and the first multiple ascending dose (MAD) cohort. Model confirms the predicted dosing regimen for phase 2, ...

LUND, SE / ACCESS Newswire / May 12, 2025 / Cantargia (STO:CANTA) Pharmacokinetic (PK) model generated based on the single ascending dose (SAD) data and the first multiple ascending dose (MAD ...

Global prevalence of Parkinson disease is projected to double by 2050, driven by aging populations and growth.

Katie Falzone; Senior Vice President, Finance; Invivyd Inc. Marc Elia; Independent Chairman of the Board; Invivyd Inc. Tim Lee; Chief Commercial Officer; Invivyd Inc ...